High Impact Factor : 7.883
Submit your paper here

Impact Factor

7.883


Call For Paper

Volume: 11 Issue 01 January 2025


Download Paper Format


Copyright Form


Share on

Review On Novel Anticancer Agent Of Dostarlimab

  • Author(s):

    S. Naveenkumar | N. Ramanathan

  • Keywords:

    Dostarliamab, Malignancy, Colorectal Cancer, Endometrial Cancer,Immunotherapy, T-Cells, PD-1/PD-L1 Inhibitors, Combination Therapy.

  • Abstract:

    One Of The Most Deadly Illnesses Of The 20th Century, Cancer Has Alarmingly Increased In The 21st, To The Point Where It Now Affects Every 4 People. Accordimg To GLOBOCAN 2020, There Were 19 Million New Cases Of Malignancy And Roughly 10 Million Cancer Re

Other Details

  • Paper id:

    IJSARTV9I1274511

  • Published in:

    Volume: 9 Issue: 12 December 2023

  • Publication Date:

    2023-12-16


Download Article